Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Innovation Trends Point To More Positives For Health Care Investors

28 Dec 2021

At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

Lucie Ellis-Taitt 22 Nov 2021

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

2020 Deal-Making Roundup

21 Sep 2021

Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

In Vivo

Deal Making Trends 2021

10 Mar 2021

Despite the chaos felt in many other sectors during the COVID-19 pandemic, pharma IPOs experienced a banner year in 2020. Understand deal making trends and business strategies as In Vivo examines the emergence of special purpose acquisition companies (SPACs) in a data-packed infographic

Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

27 Nov 2020

BIO-Europe Biopharma Deals and Financing eBook

30 Sep 2020

2020 coverage from Scrip and In Vivo provides rich insights into the attitudes and trends around deals and financing, two major engines of innovation and growth for biopharma during this current pandemic period.

The Rise of Digital Tools eBook

18 Sep 2020

Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.

Bacteria Are Blind To Politics

06 May 2020

Evan Loh, CEO of infectious disease drug developer Paratek Pharmaceuticals, explains why eliminating the DISARM ACT, which focused on finding solutions against antimicrobial resistance, from the new coronavirus aid package is a shortsighted move by US congress.

Webinar: Is Biopharma Fit For the New Decade?

12 Mar 2020

Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

Regular Acceptance Of Simulation Studies More Likely In 2020s

William Masters 17 Feb 2020

Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

Medtechs Enter The Decade of Digital, Consumers and Wellness

Ashley Yeo 11 Dec 2019

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Understand Market Access Trends in the US, Europe and Emerging Markets

08 Nov 2019

This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

02 Jul 2019

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

William Looney 02 Jul 2019

The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

Datamonitor Healthcare

World AIDS Day 2018 GlaxoSmithKline report

11 Jun 2019

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.